12:30 PM - 1:00 PM Registration and Lunch
1:00 PM - 1:05 PM Welcome and Introduction
1:05 PM – 3:20 PM Case Discussions and Interaction With Faculty Panelists
- Therapy for previously untreated stage III or IV classic Hodgkin lymphoma
- Using response-adapted treatment prior to ASCT
- Preventing or delaying second relapse after ASCT
- Therapeutic strategies for patients with disease progression after high-dose chemotherapy and ASCT (relapsed and refractory Hodgkin lymphoma
Faculty panel discussion and audience questions for each case
Novel and investigational treatment strategies will be reviewed within each case discussion
Each case discussion will include a Clinical Trial Spotlight highlighting key ongoing studies as well as a preview of studies to be presented at ASH 2018
3:20 PM - 3:30 PM Summary, Final Thoughts, and Audience Question and Answer Session
Date / Time
Joseph Connors, MD
Clinical Professor (emeritus)
Centre for Lymphoid Cancer
BC Cancer and the University of British Columbia
Robert W. Chen, MD
Department of Hematology
City of Hope
Andrew M. Evens, DO, MSc, FACP
Associate Director for Clinical Services
Rutgers Cancer Institute of New Jersey
Medical Director, Oncology Service Line
Director, Lymphoma Program
Division of Blood Disorders
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
The goal of this activity is to improve participants’ competence in and performance at selecting treatment for individual patients with Hodgkin lymphoma.
This program is intended for physicians and other healthcare providers who care for patients with Hodgkin lymphoma.
- Choose optimal intensified frontline treatments for patients with advanced Hodgkin lymphoma considering the available clinical data and newly available treatment options
- Explain the application and limitations of FDG-PET imaging in the early assessment of response to treatment in Hodgkin lymphoma
- Plan therapeutic strategies to prevent second relapse after transplant in patients with Hodgkin lymphoma at risk of progression
- Evaluate the clinical data on available and promising investigational agents for patients with relapsed/refractory Hodgkin lymphoma
- Formulate therapeutic strategies for Hodgkin lymphoma that consider the optimal sequencing of brentuximab vedotin and immune checkpoint inhibitors
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.